Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preferences for handheld vs micropump subcutaneous pertuzumab + trastuzumab in HER2-positive breast cancer
ChiCTR2500106080Phase 4Not yet recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab + pertuzumab in breast cancer, sponsored by Jiangmen Central Hospital. Primary endpoint: Patients' preference for subcutaneous injection with handheld syringe or micropump. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trastuzumab + pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500106080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106080.